Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6?

Kidney International, Supplement

Volumn 61, Issue 80, 2002, Pages

  Stenvinkel, Peter ^a   Barany, Peter ^a   Heimbur̈ger, Olof ^a   Pecoits Filho, Roberto ^a   Lindholm, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Inflammation; Interleukin 6; Malnutrition; Mortality

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BIOCOMPATIBILITY; CARDIOVASCULAR RISK; CONFERENCE PAPER; CYTOKINE PRODUCTION; HEART FAILURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEREDITY; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; MALNUTRITION; MORTALITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; ARTERIOSCLEROSIS; BLOOD; CHRONIC KIDNEY FAILURE; NUTRITIONAL DISORDER; NUTRITIONAL STATUS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; NUTRITION DISORDERS; NUTRITIONAL STATUS; RENAL DIALYSIS; RISK FACTORS;

EID: 0035999933     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.61.s80.19.x     Document Type: Conference Paper

References (59)

1. Inflammatory and atherosclerotic interactions in the depleted uremic patient
2. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leucocyte recruitment seen during acute inflammation
3. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?
4. Serum interleukin-6 in long-term hemodialysed patients
5. Elevated circulating levels of interleukin-6 in patients with chronic renal failure
6. Immunologic function and survival in hemodialysis patients
7. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
8. Interleukin-6 gene -174g>c and -572g>c promotor polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery
9. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
10. Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients
11. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
12. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
13. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients
14. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients
15. Interleukin-6 production does not increase with age
16. Elevated circulating levels of interleukin-6 in patients with chronic renal failure
17. Plasma levels of IL-1β, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients
18. Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients
19. Interleukin-8 in chronic renal failure and dialysis patients
20. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis
21. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines
22. C-reactive protein in patients with chronic renal diseases
23. The role of interleukin-6 in the failing heart
24. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL- 6 in patients with acute left heart decompensation
25. Wasting as independent risk factor for mortality in chronic heart failure
26. Blood pressure and inflammation in apparently healthy men
27. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women
28. Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-α, in vivo
29. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells
30. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: Association to chlamydia pneumoniae seropositivity
31. Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation
32. Interleukin-6 gene expression in peripheral mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis
33. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease
34. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters
35. Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production
36. Atherosclerosis: An inflammatory disease
37. Interleukin-6 exacerbates early atherosclerosis in mice
38. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells
39. Interleukin-6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: A possible role for interleukin 6 in cancer cachexia
40. Role of cytokines in inducing hyperlipidemia
41. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice
42. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo
43. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway
44. Association of inflammation and malnutrition with cardiac valve calcification in continouous ambulatory peritoneal dialysis patients
45. Production of interleukin-6, tumour necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients
46. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina
47. Cytokines and anorexia: A brief overview
48. Geriatric cachexia: The role of cytokines
49. Interleukin-6 induces skeletal muscle protein breakdown in rats
50. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsin B and L, proteasome) in C2C12 myotubes
51. Evidence for the involvement of interleukin 6 in experimental cancer cachexia
52. Interleukin-6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin-6 transgenic mice
53. Cytokine production and nutritional status in hemodialysis patients
54. Endotoxin and cytokines induce expression of leptin, the ob gene product in hamsters: A role for leptin in the anorexia of infection
55. Leptin is a negative acute phase protein in chronic hemodialysis patients
56. Effects of dialyser and dialysate on the acute phase response in clinical bicarbonate dialysis
57. Effect of high- versus low dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure
58. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type-2 diabetic patients
59. Futures trends in the treatment of rheumatoid arthritis: Cytokine targets